Adial Pharmaceuticals Receives Issue Notification for Patent Covering AD04 for the Treatment of Opioid Use Disorder Mar 26, 2020
Adial Pharmaceuticals Announces Modifications to the Phase 3 Pivotal Trial of AD04 to Protect Subjects from COVID-19 Mar 17, 2020
Adial Pharmaceuticals CEO Selected as a Luncheon Keynote Speaker for the 2020 Wall Street Conference and Retreat Feb 14, 2020
Adial Pharmaceuticals Submits Clinical Trial Applications in Six Additional European Countries Dec 19, 2019
Adial Pharmaceuticals Receives Notice of Allowance of Additional Patent for the Treatment of Alcohol Use Disorder with AD04 in Patients Identified Using a Molecular Genetic Biomarker Dec 16, 2019
Adial Completes Validation of Genetic Biomarker Test in Collaboration with Eurofins for Upcoming Phase 3 Trial Dec 13, 2019
